Dashboard
Manage Tickers

GSKGSK plc

NYSE gsk.com


$ 41.10 $ -0.11 (-0.27 %)    

Monday, 10-Jun-2024 11:21:54 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 463.96 $ 1.17 (0.25 %)
DIA $ 387.64 $ -0.71 (-0.18 %)
SPY $ 534.19 $ 0.94 (0.18 %)
TLT $ 90.87 $ -0.16 (-0.18 %)
GLD $ 213.29 $ 0.20 (0.09 %)
$ 41.21
$ 40.99
$ 41.09 x 111
$ 0.00 x 0
$ 40.97 - $ 41.19
$ 32.12 - $ 45.80
3,025,354
na
88.85B
$ 0.52
$ 14.15
TBD
na
na ($ 0.05)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

us-fda-approves-expanded-age-indication-for-gsks-arexvy-the-first-respiratory-syncytial-virus-vaccine-for-adults-aged-50-59-at-increased-risk
U.S. FDA Approves Expanded Age Indication ...
06/07/2024 23:28:16

Over 13 million US adults aged 50-59 years have a medical condition that increases their risk of severe RSV outcomes1Clinical d...

Core News & Articles
SpringWorks Therapeutics Inc Says Terminat...
06/07/2024 20:27:06

- SEC Filing

Core News & Articles
SpringWorks Therapeutics Says Termination ...
06/07/2024 20:26:22

- SEC Filing

Core News & Articles
SpringWorks Therapeutics Says Deal Termina...
06/07/2024 20:25:37

- SEC Filing

Core News & Articles
SpringWorks Therapeutics Got Notice Of Ter...
06/07/2024 20:24:07

- SEC Filing

gsks-blenrep-combo-therapy-cuts-risk-of-disease-progression-or-death-by-around-50-in-pretreated-multiple-myeloma
GSK's Blenrep Combo Therapy Cuts Risk Of D...
06/03/2024 19:08:18

GSK presented interim results from the DREAMM-8 phase 3 trial at ASCO 2024. Blenrep (belantamab mafodotin) with PomDex showed a...

why-science-applications-international-shares-are-trading-lower-by-11-here-are-other-stocks-moving-in-mondays-mid-day-session
Why Science Applications International Sha...
06/03/2024 17:56:53

zantac-heart-burn-continues-for-gsk-as-us-court-ruling-allows-thousands-of-zantac-lawsuits-to-move-forward
Zantac Heart Burn Continues For GSK As US ...
06/03/2024 13:53:20

GSK shares fell as the Delaware State Court allowed over 70,000 lawsuits regarding the discontinued heartburn drug Zantac (rani...

gsk-reported-longer-term-results-from-phase-ii-supported-collaborative-study-with-memorial-sloan-kettering-cancer-center-evaluating-jemperli-as-first-line-treatmentas-surgery-alternative-for-mismatch-repair-deficient-locally-advanced-rectal-cancer
GSK Reported Longer-term Results From Phas...
06/03/2024 12:21:03

gsk-boston-beer-and-other-big-stocks-moving-lower-in-mondays-pre-market-session
GSK, Boston Beer And Other Big Stocks Movi...
06/03/2024 12:13:57

why-gamestop-shares-are-trading-higher-here-are-20-stocks-moving-premarket
Why GameStop Shares Are Trading Higher; He...
06/03/2024 09:35:57

saturday-gsk-said-it-disagrees-with-ruling-by-delaware-state-court-that-contradicts--federal-courts-multidistrict-litigation-ruling-which-dismissed-all-cases-alleging-five-cancer-types-in-december-2022-gsk-said-it-will-immediately-seek-an-appeal
Saturday, GSK Said It Disagrees With Rulin...
06/03/2024 08:31:37

https://www.gsk.com/en-gb/media/press-releases/statement-zantac-ranitidine-litigation-delaware-state-court-daubert-ruling/

reported-earlier-gsks-interim-analysis-of-the-dreamm-8-phase-iii-head-to-head-trial-evaluating-belantamab-mafodotin-combination-shows-50-reduction-in-disease-progression-risk-in-multiple-myeloma
Reported Earlier, GSK's Interim Analysis O...
06/03/2024 06:56:09

DREAMM-8 phase III trial showed statistically significant and clinically meaningful improvement in primary endpoint of progre...

goldman-sachs-initiates-coverage-on-gsk-with-neutral-rating-announces-price-target-of-47
Goldman Sachs Initiates Coverage On GSK wi...
05/30/2024 10:44:17

Goldman Sachs analyst Rajan Sharma initiates coverage on GSK (NYSE:GSK) with a Neutral rating and announces Price Target of ...

Core News & Articles
CureVac Has Dosed The First Participant In...
05/28/2024 11:17:48

astrazeneca-merck-gsk-struck-record-441b-licensing-deals-with-chinese-drugmakers-in-2023-report
AstraZeneca, Merck, GSK Struck Record $44....
05/27/2024 11:12:58

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

zantac-verdict-jury-finds-no-link-to-colon-cancer-in-initial-trial-gsk-and-boehringer-prevail-in-first-zantac-cancer-lawsuit
Zantac Verdict: Jury Finds No Link To Colo...
05/24/2024 17:45:32

Chicago jury rejects woman's claim that Zantac caused her colon cancer. First of thousands of similar lawsuits, companies d...

jury-rules-zantac-not-a-cause-of-womans-cancer-in-first-trial-over-drug
Jury Rules Zantac Not A Cause Of Woman's C...
05/23/2024 17:02:34

- Reuters

first-advanced-oral-treatment-for-asthma---sanofis-investigational-drug-shows-potential
First Advanced Oral Treatment For Asthma -...
05/22/2024 17:59:47

Sanofi reveals Phase 2 results for rilzabrutinib in moderate-to-severe asthma. High and low doses showed a reduction in asthma ...

gsk-concealed-risk-associated-with-discontinued-heart-burn-drug-zantac-whistleblower-lawsuit-claims
GSK Concealed Risk Associated With Discont...
05/21/2024 16:48:38

Valisure sues GSK accusing the company of hiding cancer risks linked to Zantac, potentially defrauding the U.S. government. Thi...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION